New approach methodologies (NAMs) are gaining momentum worldwide as regulators and researchers work to reduce reliance on animal testing. Human-relevant 3D cell models, such as spheroids, organoids and organ-on-a-chip/microphysiological systems (MPS), are increasingly used in drug discovery and safety assessment. However, their responses change over time and can vary between samples, which makes them difficult to capture with a single endpoint measurement.
In this webinar, we will look at where NAMs and 3D cell models stand today, and how live-cell imaging can complement endpoint assays by following treatment responses over time in the same sample.